Defining and treating moderate plaque psoriasis: a dermatologist survey
Purpose: Patients with moderate plaque psoriasis are often undertreated and may experience unsatisfactory clinical outcomes. Undertreatment may stem partly from a lack of consensus on the definition of moderate psoriasis and appropriate treatments for patients with moderate disease severity. Materia...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2018-10-01
|
| Series: | Journal of Dermatological Treatment |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/09546634.2018.1443200 |
| _version_ | 1797683752441217024 |
|---|---|
| author | Melissa L. F. Knuckles Eugenia Levi Jennifer Soung |
| author_facet | Melissa L. F. Knuckles Eugenia Levi Jennifer Soung |
| author_sort | Melissa L. F. Knuckles |
| collection | DOAJ |
| description | Purpose: Patients with moderate plaque psoriasis are often undertreated and may experience unsatisfactory clinical outcomes. Undertreatment may stem partly from a lack of consensus on the definition of moderate psoriasis and appropriate treatments for patients with moderate disease severity. Materials and Methods: An online survey was conducted during October 2015 to determine how US dermatologists in the clinical setting define and treat moderate psoriasis. Results: A total of 150 dermatologists responded to the survey (mean time in practice: 13.5 years). On average, they saw 72 patients with psoriasis per month; 40% of these patients were considered to have moderate psoriasis. Most (95%) reported assessing disease severity based on the percentage of psoriasis-affected body surface area (BSA); 59% also considered location of the affected area. BSA cutoffs used to define moderate psoriasis varied widely (median low and high cutoffs: 5–10%; range: 1–70%). Similarly, wide variation in cutoff ranges was observed for the Psoriasis Area and Severity Index (PASI), Physician Global Assessment (PGA), and Dermatology Life Quality Index (DLQI). Primary therapy comprised biologics (47%), prescription topicals (28%), and oral systemics (18%). Conclusions: The current findings indicate lack of consensus surrounding the definition of moderate psoriasis among US dermatologists. |
| first_indexed | 2024-03-12T00:19:22Z |
| format | Article |
| id | doaj.art-96e789e5c9a2495c85edc6cff2264f99 |
| institution | Directory Open Access Journal |
| issn | 0954-6634 1471-1753 |
| language | English |
| last_indexed | 2024-03-12T00:19:22Z |
| publishDate | 2018-10-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Journal of Dermatological Treatment |
| spelling | doaj.art-96e789e5c9a2495c85edc6cff2264f992023-09-15T14:08:32ZengTaylor & Francis GroupJournal of Dermatological Treatment0954-66341471-17532018-10-0129765866310.1080/09546634.2018.14432001443200Defining and treating moderate plaque psoriasis: a dermatologist surveyMelissa L. F. Knuckles0Eugenia Levi1Jennifer Soung2Department of DermatologyCelgene CorporationSouthern California DermatologyPurpose: Patients with moderate plaque psoriasis are often undertreated and may experience unsatisfactory clinical outcomes. Undertreatment may stem partly from a lack of consensus on the definition of moderate psoriasis and appropriate treatments for patients with moderate disease severity. Materials and Methods: An online survey was conducted during October 2015 to determine how US dermatologists in the clinical setting define and treat moderate psoriasis. Results: A total of 150 dermatologists responded to the survey (mean time in practice: 13.5 years). On average, they saw 72 patients with psoriasis per month; 40% of these patients were considered to have moderate psoriasis. Most (95%) reported assessing disease severity based on the percentage of psoriasis-affected body surface area (BSA); 59% also considered location of the affected area. BSA cutoffs used to define moderate psoriasis varied widely (median low and high cutoffs: 5–10%; range: 1–70%). Similarly, wide variation in cutoff ranges was observed for the Psoriasis Area and Severity Index (PASI), Physician Global Assessment (PGA), and Dermatology Life Quality Index (DLQI). Primary therapy comprised biologics (47%), prescription topicals (28%), and oral systemics (18%). Conclusions: The current findings indicate lack of consensus surrounding the definition of moderate psoriasis among US dermatologists.http://dx.doi.org/10.1080/09546634.2018.1443200psoriasisonline surveydermatologistsdisease severitytreatment |
| spellingShingle | Melissa L. F. Knuckles Eugenia Levi Jennifer Soung Defining and treating moderate plaque psoriasis: a dermatologist survey Journal of Dermatological Treatment psoriasis online survey dermatologists disease severity treatment |
| title | Defining and treating moderate plaque psoriasis: a dermatologist survey |
| title_full | Defining and treating moderate plaque psoriasis: a dermatologist survey |
| title_fullStr | Defining and treating moderate plaque psoriasis: a dermatologist survey |
| title_full_unstemmed | Defining and treating moderate plaque psoriasis: a dermatologist survey |
| title_short | Defining and treating moderate plaque psoriasis: a dermatologist survey |
| title_sort | defining and treating moderate plaque psoriasis a dermatologist survey |
| topic | psoriasis online survey dermatologists disease severity treatment |
| url | http://dx.doi.org/10.1080/09546634.2018.1443200 |
| work_keys_str_mv | AT melissalfknuckles definingandtreatingmoderateplaquepsoriasisadermatologistsurvey AT eugenialevi definingandtreatingmoderateplaquepsoriasisadermatologistsurvey AT jennifersoung definingandtreatingmoderateplaquepsoriasisadermatologistsurvey |